With 8,000 Points Approaching... Should You Buy Large Caps Now or Not?
Samsung Electronics and SK hynix are currently experiencing a correction due to profit-taking. However, even now, it could present an opportunity.
■ CEO Huh Haenam's "Divine Move" Gains Popularity Among Individual Investors (Click)
CEO Huh Haenam offers the following advice to individual investors.
If you missed out on the KOSDAQ rally last week, there is no need to blame yourself. In fact, now is a buying opportunity at a pullback. The first correction phase after surpassing the 1,200-point level has always been the best entry point. With expert Huh Haenam, you can turn this opportunity into profit.
■ Join now and instantly check recommended stocks and tomorrow's strategy notes! (Click)
If you have only been watching the KOSPI until yesterday, this week may be your last rational entry opportunity. With the KOSPI's price-earnings ratio in the 7x range, which is extremely undervalued compared to major global markets, the speed at which this valuation gap narrows could be faster than expected, so keep this in mind.
Before the market opened today, expert Huh Haenam urgently selected two stocks showing the strongest buy signals in this supply-demand reversal structure. These are stocks that overlap with the shipbuilding and AI themes, and according to the securities industry, accumulation is already quietly underway. Check them for free now on CEO Huh Haenam's public channel.
Recently hot issue stocks:
Eluon, Mobiis, GCMS, LG Electronics, Inno Instrument
Hot Picks Today
Even with High Oil Price Relief Payment, Additional 300,000 Won Per Person to Be Provided... Applications Open from the 18th in This Region
- "Those Who Hesitated at 3,000 Still Haven't Bought" 7 Trillion-Won Asset Manager Says "Opportunities Remain" [Investment Strategies of the Wealthy] ⑦
- Shin Ramyun Surpasses KRW 20 Trillion in Cumulative Sales, Marking a New Chapter in K-Ramen History
- Investment Warnings Surge... "Warning Light" Flashes as KOSPI Nears 8,000 Points
- 'Drugs to Prevent Aging' Enter Their First Target Year... First Patient Dosed in the US [New Path for Bio, Anti-Aging] ①
※ The content above is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.